EPOK Therapeutics
The startup develops clinical-stage biopharmaceuticals focused on antibody-drug conjugates that target the erythropoietin (EPO) receptor to treat anemia in patients with chronic kidney disease (CKD). Its lead product candidate utilizes recombinant human erythropoietin to enhance red blood cell production, addressing the significant health issue of anemia associated with CKD.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$6.7MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops clinical-stage biopharmaceuticals focused on antibody-drug conjugates that target the erythropoietin (EPO) receptor to treat anemia in patients with chronic kidney disease (CKD). Its lead product candidate utilizes recombinant human erythropoietin to enhance red blood cell production, addressing the significant health issue of anemia associated with CKD.